Stimuli-sensitive thiolated hyaluronic acid based nanofibers: Synthesis, preclinical safety and in vitro anti-HIV activity

Nanomedicine

Volumn 11, Issue 22, 2016, Pages 2935-2958

  Agrahari, Vivek ^a   Meng, Jianing ^a   Ezoulin, Miezan J M ^a   Youm, Ibrahima ^a,b   Dim, Daniel C ^c   Molteni, Agostino ^c   Hung, Wei Ting ^d   Christenson, Lane K ^d   Youan, Bi Botti C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b HOUGH EAR INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

anti HIV activity; electrospinning; HIV vaginal transmission; nanofibers; preclinical safety; tenofovir; thiolated hyaluronic acid; topical microbicide; vaginal delivery

Indexed keywords

HYALURONIC ACID; NANOPARTICLE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NANOFIBER; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; ELECTROSPINNING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LUCIFERASE ASSAY; MOUSE; MUCOADHESION; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; HIV INFECTIONS; REPRODUCTIVE TRACT INFECTIONS; TRANSMISSION; VAGINA; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; DRUG LIBERATION; FEMALE; HIV INFECTIONS; HUMANS; HYALURONIC ACID; MICE; NANOFIBERS; REPRODUCTIVE TRACT INFECTIONS; SULFHYDRYL COMPOUNDS; TENOFOVIR; VAGINA;

EID: 84994618725     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0103     Document Type: Article

References (95)

1. Granich R, Gupta S, Hersh B et al. Trends in AIDS deaths, new infections and ART coverage in the Top 30 countries with the highest AIDS mortality burden; 1990-2013. PLoS ONE 10(7), e0131353 (2015).
2. Agrahari V, Zhang C, Zhang T et al. Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro. AAPS J. 16(2), 181-193 (2014).
3. Sanchez-Rodriguez J, Vacas-Cordoba E, Gomez R, De La Mata FJ, Munoz-Fernandez MA. Nanotech-derived topical microbicides for HIV prevention: The road to clinical development. Antiviral Res. 113, 33-48 (2015).
4. Vanic Z, Skalko-Basnet N. Nanopharmaceuticals for improved topical vaginal therapy: can they deliver Eur. J. Pharm. Sci. 50(1), 29-41 (2013).
5. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug. Deliv. Rev. 57(11), 1692-1712 (2005).
6. Oh EJ, Park K, Kim KS et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J. Control. Release 141(1), 2-12 (2010).
7. Mizrahy S, Raz SR, Hasgaard M et al. Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Control. Release 156(2), 231-238 (2011).
8. Jhan HJ, Liu JJ, Chen YC, Liu DZ, Sheu MT, Ho HO. Novel injectable thermosensitive hydrogels for delivering hyaluronic acid-doxorubicin nanocomplexes to locally treat tumors. Nanomedicine (Lond.) 10(8), 1263-1274 (2015).
9. Urbiola K, Sanmartin C, Blanco-Fernandez L, Tros De Ilarduya C. Efficient targeted gene delivery by a novel PAMAM/DNA dendriplex coated with hyaluronic acid. Nanomedicine (Lond.) 9(18), 2787-2801 (2014).
10. Jung HS, Kim KS, Yun SH, Hahn SK. Enhancing the transdermal penetration of nanoconstructs: could hyaluronic acid be the key Nanomedicine (Lond.) 9(6), 743-745 (2014).
11. Youm I, Agrahari V, Murowchick JB, Youan BB. Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells. Pharm. Res. 31(9), 2439-2452 (2014).
12. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Zerrouk N, Caramella C. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcinebuccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J. Pharm. Pharmacol. 56(9), 1083-1090 (2004).
13. Leitner VM, Walker GF, Bernkop-Schnurch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm. 56(2), 207-214 (2003).
14. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168-1174 (2010).
15. Das Neves J, Nunes R, Rodrigues F, Sarmento B. Nanomedicine in the development of anti-HIV microbicides. Adv. Drug Deliv. Rev. 103, 57-75 (2016).
16. Sill TJ, Von Recum HA. Electrospinning: Applications in drug delivery and tissue engineering. Biomaterials 29(13), 1989-2006 (2008).
17. Nista SV, Bettini J, Mei LH. Coaxial nanofibers of chitosanalginate-PEO polycomplex obtained by electrospinning. Carbohydr. Polym. 127, 222-228 (2015).
18. Blakney AK, Ball C, Krogstad EA, Woodrow KA. Electrospun fibers for vaginal anti-HIV drug delivery. Antiviral Res. 100(Suppl.), S9-S16 (2013).
19. Tseng YY, Liu SJ. Nanofibers used for the delivery of analgesics. Nanomedicine (Lond.) 10(11), 1785-1800 (2015).
20. Agrahari V, Youan BB. Sensitive and rapid HPLC quantification of tenofovir from hyaluronic acidbased nanomedicine. AAPS PharmSciTech 13(1), 202-210 (2012).
21. Dezzutti CS, Shetler C, Mahalingam A et al. Safety and efficacy of tenofovir/IQP-0528 combination gels-a dual compartment microbicide for HIV-1 prevention. Antiviral Res. 96(2), 221-225 (2012).
22. Saxena BB, Han YA, Fu D et al. Sustained release of microbicides by newly engineered vaginal rings. AIDS 23(8), 917-922 (2009).
23. Alukda D, Sturgis T, Youan BB. Formulation of tenofovirloaded functionalized solid lipid nanoparticles intended for HIV prevention. J. Pharm. Sci. 100(8), 3345-3356 (2011).
24. Meng J, Sturgis TF, Youan BB. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur. J. Pharm. Sci. 44(1-2), 57-67 (2011).
25. Meng J, Zhang T, Agrahari V, Ezoulin MJ, Youan BB. Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention. Nanomedicine (Lond.) 9(11), 1595-1612 (2014).
26. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur. J. Pharm. Biopharm. 79(3), 526-536 (2011).
27. Zhang T, Zhang C, Agrahari V, Murowchick JB, Oyler NA, Youan BB. Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention. Antiviral Res. 97(3), 34-46 (2012).
28. Huang C, Soenen SJ, Van Gulck E et al. Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery. Biomaterials 33(3), 962-969 (2012).
29. Blakney AK, Krogstad EA, Jiang YH, Woodrow KA. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int. J. Nanomedicine 9, 2967-2978 (2014).
30. Schanté CE, Zubera G, Herlin C, Vandamme TF. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr. Polym. 85, 469-489 (2011).
31. Swyer GI. The hyaluronidase content of semen. Biochem. J. 41(3), 409-413 (1947).
32. Abdul-Aziz M, Maclusky NJ, Bhavnani BR, Casper RF. Hyaluronidase activity in human semen: correlation with fertilization in vitro. Fertil. Steril. 64(6), 1147-1153 (1995).
33. Reese KL, Aravindan RG, Griffiths GS et al. Acidic hyaluronidase activity is present in mouse sperm and is reduced in the absence of SPAM1: evidence for a role for hyaluronidase 3 in mouse and human sperm. Mol. Reprod. Dev. 77(9), 759-772 (2010).
34. Stern R, Kogan G, Jedrzejas MJ, Soltes L. The many ways to cleave hyaluronan. Biotechnol. Adv. 25(6), 537-557 (2007).
35. Sabatte J, Remes Lenicov F, Cabrini M et al. The role of semen in sexual transmission of HIV: beyond a carrier for virus particles. Microbes. Infect. 13(12-13), 977-982 (2011).
36. Serban MA, Yang G, Prestwich GD. Synthesis, characterization and chondroprotective properties of a hyaluronan thioethyl ether derivative. Biomaterials 29(10), 1388-1399 (2008).
37. Ellman GL. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82(1), 70-77 (1959).
38. Liang D, Hsiao BS, Chu B. Functional electrospun nanofibrous scaffolds for biomedical applications. Adv. Drug Deliv. Rev. 59(14), 1392-1412 (2007).
39. Ji Y, Ghosh K, Shu XZ et al. Electrospun three-dimensional hyaluronic acid nanofibrous scaffolds. Biomaterials 27(20), 3782-3792 (2006).
40. Ji Y, Ghosh K, Li B, Sokolov JC, Clark RA, Rafailovich MH. Dual-syringe reactive electrospinning of cross-linked hyaluronic acid hydrogel nanofibers for tissue engineering applications. Macromol. Biosci. 6(10), 811-817 (2006).
41. Bhattarai N, Edmondson D, Veiseh O, Matsen FA, Zhang M. Electrospun chitosan-based nanofibers and their cellular compatibility. Biomaterials 26(31), 6176-6184 (2005).
42. Hu X, Liu S, Zhou G, Huang Y, Xie Z, Jing X. Electrospinning of polymeric nanofibers for drug delivery applications. J. Control. Release 185, 12-21 (2014).
43. Zamani M, Prabhakaran MP, Ramakrishna S. Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int. J. Nanomedicine 8, 2997-3017 (2013).
44. Agrahari V, Putty S, Mathes C, Murowchick JB, Youan BB. Evaluation of degradation kinetics and physicochemical stability of tenofovir. Drug Test. Anal. 7(3), 207-213 (2015).
45. Takeuchi H, Thongborisute J, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv. Drug Deliv. Rev. 57(11), 1583-1594 (2005).
46. Das Neves J, Rocha CM, Goncalves MP et al. Interactions of microbicide nanoparticles with a simulated vaginal fluid. Mol. Pharm. 9(11), 3347-3356 (2012).
47. Svensson O, Thuresson K, Arnebrant T. Interactions between drug delivery particles and mucin in solution and at interfaces. Langmuir 24(6), 2573-2579 (2008).
48. Svensson O, Thuresson K, Arnebrant T. Interactions between chitosan-modified particles and mucin-coated surfaces. J. Colloid Interface Sci. 325(2), 346-350 (2008).
49. Ivarsson D, Wahlgren M. Comparison of in vitro methods of measuring mucoadhesion: ellipsometry, tensile strength and rheological measurements. Colloids Surf. B. Biointerfaces 92, 353-359 (2012).
50. Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J. Androl. 26(4), 459-469 (2005).
51. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 59(2), 91-95 (1999).
52. Svensson O. Interactions of Mucins with Biopolymers and Drug Delivery Particles [PhD Thesis]. Malmö University, MalmöSweden (2008).
53. Lindh L, Glantz P-O, Carlstedt I, Wickstro C, Arnebrant T. Adsorption of MUC5B and the role of mucins in early salivary film formation. Colloids Surf. B. Biointerfaces 25, 139-146 (2002).
54. Schmohl A, Khan A, Hess P. Functionalization of oxidized silicon surfaces with methyl groups and their characterization. Superlattices Microst. 36, 113-121 (2004).
55. George JP, Smet PF, Botterman J et al. Lanthanide-assisted deposition of strongly electro-optic PZT thin films on silicon: Toward integrated active nanophotonic devices. ACS Appl. Mater. Interfaces 7(24), 13350-13359 (2015).
56. Theisen A, Johann C, Deacon MP, Harding SE. Refractive Increment Data-Book for Polymer and Biomolecular Scientists. Nottingham University Press, Nottingham, UK (2000).
57. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13(2), 123-133 (2001).
58. Zhang Y, Huo M, Zhou J et al. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 12(3), 263-271 (2010).
59. Petrova MI, Van Den Broek M, Balzarini J, Vanderleyden J, Lebeer S. Vaginal microbiota and its role in HIV transmission and infection. FEMS Microbiol. Rev. 37(5), 762-792 (2013).
60. Moncla BJ, Pryke K, Rohan LC, Yang H. Testing of viscous anti-HIV microbicides using Lactobacillus. J. Microbiol. Methods 88(2), 292-296 (2012).
61. Catalone BJ, Kish-Catalone TM, Budgeon LR et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob. Agents Chemother. 48(5), 1837-1847 (2004).
62. McLean AC, Valenzuela N, Fai S, Bennett SA. Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J. Vis. Exp. 67, e4389 (2012).
63. Ham AS, Nugent ST, Peters JJ et al. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. Antiviral Res. 120, 153-164 (2015).
64. Garcia JM, Gao A, He PL et al. High-throughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV-1 inhibitors in a cellbased assay. Antiviral Res. 81(3), 239-247 (2009).
65. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259), 263-267 (1996).
66. Young J, Tang Z, Yu Q, Yu D, Wu Y. Selective killing of HIV-1-positive macrophages and T cells by the Revdependent lentivirus carrying anthrolysin O from Bacillus anthracis. Retrovirology 5, 36 (2008).
67. Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 27(5), 796-810 (2010).
68. Kramberger P, Ciringer M, Strancar A, Peterka M. Evaluation of nanoparticle tracking analysis for total virus particle determination. Virol. J. 9, 265 (2012).
69. Zhong P, Agosto LM, Ilinskaya A et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS ONE 8(1), e53138 (2013).
70. Ivetac A, Swift SE, Boyer PL et al. Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles. Chem. Biol. Drug Des. 83(5), 521-531 (2014).
71. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 22(3), 659-661 (2008).
72. Guo J, Meng F, Li L, Zhong B, Zhao Y. Development and validation of an LC/MS/MS method for the determination of tenofovir in monkey plasma. Biol. Pharm. Bull. 34(6), 877-882 (2011).
73. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs. Biomed. 99(3), 306-314 (2010).
74. Choi KY, Min KH, Yoon HY et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 32(7), 1880-1889 (2011).
75. Li X, Yu G, Jin K, Yin Z. Hyaluronic acid L-cysteine conjugate exhibits controlled-release potential for mucoadhesive drug delivery. Pharmazie 67(3), 224-228 (2012).
76. Yadav S, Ahuja M, Kumar A, Kaur H. Gellan-thioglycolic acid conjugate: synthesis, characterization and evaluation as mucoadhesive polymer. Carbohydr. Polym. 99, 601-607 (2014).
77. Tu Luan, Lijiao Wu, Hongbin Zhang, Wang Y. A study on the nature of intermolecular links in the cryotropic weak gels of hyaluronan. Carbohydr. Polym. 87, 2076-2085 (2012).
78. Bhardwaj N, Kundu SC. Electrospinning: A fascinating fiber fabrication technique. Biotechnol. Adv. 28(3), 325-347 (2010).
79. Mckee MG, Wilkes GL, Colby RH, Long TE. Correlations of solution rheology with electrospun fiber formation of linear and branched polyesters. Macromolecules 37(5), 1760-1767 (2004).
80. Choi SU, Bui T, Ho RJ. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J. Pharm. Sci. 97(2), 931-943 (2008).
81. Lenormand H, Vincent JC. pH effects on the hyaluronan hydrolysis catalysed by hyaluronidase in the presence of proteins: Part II. The electrostatic hyaluronan-Protein complexes. Carbohydr. Polym. 85, 303-311 (2011).
82. Ferir G, Vermeire K, Huskens D et al. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydratebinding agents (CBAs). Antiviral Res. 90(3), 200-204 (2011).
83. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J. Allergy. Clin. Immunol. 122(1), 3-9; quiz 10-11 (2008).
84. Rat P, Korwin-Zmijowska C, Warnet JM, Adolphe M. New in vitro fluorimetric microtitration assays for toxicological screening of drugs. Cell Biol. Toxicol. 10(5-6), 329-337 (1994).
85. Mesquita PM, Cheshenko N, Wilson SS et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J. Infect. Dis. 200(4), 599-608 (2009).
86. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1(1), 25-34 (2003).
87. Adriaens E, Remon JP. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex. Transm. Dis. 35(5), 512-516 (2008).
88. Fuchs EJ, Lee LA, Torbenson MS et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J. Infect. Dis. 195(5), 703-710 (2007).
89. Connolly NC, Riddler SA, Rinaldo CR. Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev. 7(3), 168-180 (2005).
90. Introini A, Vanpouille C, Lisco A, Grivel JC, Margolis L. Interleukin-7 facilitates HIV-1 transmission to cervicovaginal tissue ex vivo. PLoS Pathog. 9(2), e1003148 (2013).
91. Vandergeeten C, Fromentin R, Dafonseca S et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121(21), 4321-4329 (2013).
92. Blish CA, Mcclelland RS, Richardson BA et al. Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. J. Acquir. Immune. Defic. Syndr. 61(4), 436-440 (2012).
93. Das Neves J, Araujo F, Andrade F, Amiji M, Bahia MF, Sarmento B. Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm. Res. 31(7), 1834-1845 (2014).
94. Darville T, Andrews CW Jr., Sikes JD, Fraley PL, Rank RG. Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection. Infect. Immun. 69(6), 3556-3561 (2001).
95. Packiam M, Veit SJ, Anderson DJ, Ingalls RR, Jerse AE. Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses. Infect. Immun. 78(1), 433-440 (2010).